Role of Inflammation in Heart Failure

Current Atherosclerosis Reports

Volumn 19, Issue 6, 2017, Pages

  Shirazi, Lily F ^a   Bissett, Joe ^a   Romeo, Francesco ^a,b   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cytokines; Heart failure; Immune cells; Inflammation; Leukocytes; Mediators

Indexed keywords

ANTIINFLAMMATORY AGENT; CELACADE; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE COURSE; HEART FAILURE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; ANIMAL; COMPLICATION; IMMUNOLOGY;

ANIMALS; ANTI-ALLERGIC AGENTS; CYTOKINES; HEART FAILURE; HUMANS; INFLAMMATION; LEUKOCYTES;

EID: 85018462078     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0660-3     Document Type: Review

References (56)

1. st century. Heart. 2003;89(1):49–53.
2. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–9.
3. • Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–68. This review discusses the role of inflammation and heart failure, in light of new understanding of innate immunity.
4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–41.
5. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19(9):819–24.
6. Awad AE, Kandalam V, Chakrabarti S, et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010;298(3):C679–92.
7. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–6.
8. Van Tassell BW, Seropian IM, Toldo S, Mezzaroma E, Abbate A. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013;62(7):637–40.
9. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949–58.
10. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438.
11. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008;153(Suppl 1):S414–27.
12. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol. 2007;102(5):393–411.
13. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122(2):145–55.
14. Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62–8.
15. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69(1):164–77.
16. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, et al. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.
17. Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2001;16(1):68–75.
18. Trofimov ES, Poskrebysheva AS. Study on activity of inflammatory factors in patients with chronic heart failure depending on the stage of the disease and NYHA class. Bull Exp Biol Med. 2015;158(5):614–6.
19. Li XF, Pan D, Zhang WL, Zhou J, Liang JJ. Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients. Genet Mol Res. 2016;15(2).
20. Zhou SF, Yuan J, Liao MY, Xia N, Tang TT, Li JJ, Jiao J, Dong WY, Nie SF, Zhu ZF, Zhang WC, Lv BJ, Xiao H, Wang Q, Tu X, Liao YH, Shi GP, Cheng X. IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med (Berl). 2014;92(10):1105–16.
21. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase I reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A. 2001;98:2871–6.
22. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019–30.
23. Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D. Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology. 2016;221(3):412–7.
24. Roselló-Lletí E, Rivera M, Bertomeu V, Cortés R, Jordán A, González-Molina A. Interleukin-4 and cardiac fibrosis in patients with heart failure. Rev Esp Cardiol. 2007;60(7):777–80.
25. Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, Rhaleb N, Carretero OA, Rhaleb NE. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension. 2015;66(3):582–9.
26. Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J. 2010;12(3):158–62.
27. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg. 2003;76(1):117–23.
28. Adampoulos S, Parissis JT, Parraskevaidis I, Karatzas D, Livanis E, Georgiadis M, Karavolias G, Mitropoulos D, Degiannis D, Kremastinos DT. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2003;24(24):2186–96.
29. Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther. 2012;30(1):e30–40.
30. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103:485–92.
31. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB, Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–91.
32. Van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, Van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6(2):219–26.
33. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Hermann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–23.
34. McEvoy JW, Chen Y, Halushka MK, Christenson E, Ballantyne CM, Blumenthal RS, Christenson RH, Selvin E. Galectin-3 and risk of heart failure and death in blacks and whites. J Am Heart Assoc. 2016;5(5).
35. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57–70.
36. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, O’Conner CM. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6(6):1172–9.
37. • Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131(11):1019–30. This review discusses the interaction between immune cells and inflammatory signaling, with implications toward therapeutic targets.
38. • Mehta JL, Pothineni NVK. Inflammation in heart failure: the holy grail? Hypertension. 2016;68:27–9. This review discusses the different effects of inflammation in acute versus chronic setting, particularly emphasizing the role of regulatory T cells.
39. •• Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum.”. J Am Coll Cardiol. 2016;67(9):1091–103. This review discusses the role of immune cells and inflammatory signaling in cardiovascular diseases, emphasizing the role of leukocytes.
40. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161–6.
41. Aharinejad S, Abraham D, Paulus P, Zins K, Hofmann M, Michlits W, Gyöngyösi M, Macfelda K, Lucas T, Trescher K, Grimm M, Stanley ER. Colony-stimulating factor-1 transfection of myoblasts improves the repair of the failing myocardium following autologous myoblast transplantation. Cardiovasc Res. 2008;79:395–404.
42. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106:1646–55.
43. Kain D, Amit U, Yagil C, Landa N, Naftali-Shani- N, Molotski N, Aviv V, Feinberg MS, Goitein O, Kushnir T, Konen E, Epstein FH, Yagil Y, Leor J. Macrophages dictate the progression and manifestation of hypertensive heart disease. Int J Cardiol. 2016;203:381–95.
44. Leuschner F, Courties G, Dutta P, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36:1478–88.
45. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.
46. Mann DL, McMurray JJV, Packer M, et al. Targeted anti-cytokine therapy in patients with chronic heart failure: results of the Randomized Etancercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602.
47. Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112:3408–14.
48. Parrillo JE, Cunnion RE, Epstein SE, Parker ME, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS. A prospective randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–8.
49. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083–8.
50. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998;351:1091–3.
51. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, Skudicky D, Sareli P. Effects of pentoxifylline on left-ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;90:1118–22.
52. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, Zambakides C, Peters F, Essop R. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004;109:750–5.
53. Torre-Amione G, Anker SD, Bourge RC, et al. Advanced chronic heart failure clinical assessment of immune modulation therapy investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomized trial. Lancet. 2008;371:228–36.
54. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ucland T, Lien E, Frøland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–5.
55. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–9.
56. Moreira DM, Vieira JL, Gottschall CA. The effects of METhotrexate therapy on the physical capacity of patients with ISchemia heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail. 2009;15:828–34.